Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Selling Tetraphase Pharmaceuticals Inc (TTPH)

Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly interesting group of stocks that hedge funds like is the small-caps. The huge amount of capital does not allow hedge funds to invest a lot in small-caps, but our research showed that their most popular small-cap ideas are less efficiently priced and generate stronger returns than their large- and mega-cap picks and the broader market. That is why we follow the hedge fund activity in the small-cap space.

On the back of disappointing trial results, Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)’s stock plunged on September 9, which caused many large investors to head for the exits. The stock was in 15 hedge funds’ portfolios at the end of September, compared to 21 hedge funds in our database with TTPH holdings at the end of the previous quarter. At the end of this article we will also compare TTPH to other stocks, including The York Water Company (NASDAQ:YORW), Akarti Therapeutics PLC (ADR) (NASDAQ:AKTX), and Trinity Biotech plc (ADR) (NASDAQ:TRIB) to get a better sense of its popularity.

Follow Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)
Trade (NASDAQ:TTPH) Now!

Today there are a lot of metrics stock traders use to grade stocks. Two of the most under-the-radar metrics are hedge fund and insider trading indicators. Our experts have shown that, historically, those who follow the best picks of the top hedge fund managers can outperform the S&P 500 by a superb margin (see the details here).

With all of this in mind, let’s review the latest action surrounding Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH).

Hedge fund activity in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)

Heading into Q4, a total of 15 of the hedge funds tracked by Insider Monkey were bullish on this stock, a drop of  29% from the previous quarter. With hedge funds’ capital changing hands, there exists an “upper tier” of noteworthy hedge fund managers who were upping their holdings considerably (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Great Point Partners, managed by Jeffrey Jay and David Kroin, holds the number one position in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH). Great Point Partners has a $8.4 million position in the stock, comprising 3.3% of its 13F portfolio. On Great Point Partners’s heels is Sectoral Asset Management, led by Jerome Pfund and Michael Sjostrom, holding a $5.2 million position; the fund has 0.2% of its 13F portfolio invested in the stock. Other professional money managers that are bullish include Farallon Capital, Howard Guberman’s Gruss Asset Management, and Israel Englander’s Millennium Management.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.